MedTrace Logo

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

NCT04493632 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-04-30

No results posted yet for this study

Summary

The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.

The Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.

Conditions

  • Pancreatic Neoplasm
  • Digestive System Neoplasm
  • Neoplasms by Site
  • Neoplasms
  • Endocrine Gland Neoplasm
  • Digestive System Disease
  • Pancreatic Diseases
  • Endocrine System Diseases

Sponsors & Collaborators

  • OncoSil Medical Limited

    lead INDUSTRY

Principal Investigators

  • Paul J Ross, MRCP, MBBS · Guy's and St Thomas' NHS Foundation Trust, London, UK

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-12
Primary Completion
2025-11-01
Completion
2027-10-01

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493632 on ClinicalTrials.gov